COVID-19: Why Do Some People Get Seriously Ill?


The body’s first encounter with SARS-CoV-2, the virus behind COVID-19, happens in the nose and throat, or nasopharynx. A new study in the journal Cell suggests that the first responses in this battleground help determine who will develop severe disease and who will get through with mild or no illness.

Building on work published last year identifying SARS-CoV-2-susceptible cells, a team of collaborators at Boston Children’s Hospital, MIT, and the University of Mississippi Medical Center comprehensively mapped SARS-CoV-2 infection in the nasopharynx.

They obtained samples from the nasal swabs of 35 adults with COVID-19 from April to September 2020, ranging from mildly symptomatic to critically ill. They also got swabs from 17 control subjects and six patients who were intubated but did not have COVID-19.

“Why some people get more sick than others has been one of the most puzzling aspects of this virus from the beginning,” says José Ordovás-Montañés, Ph.D., of Boston Children’s, co-senior investigator on the study with Bruce Horwitz, MD, Ph.D. of Boston Children’s, Alex K. Shalek, Ph.D., of MIT and Sarah Glover, DO, of the University of Mississippi. “Many studies looking for risk predictors have looked for signatures in the blood, but blood may not really be the right place to look.”

COVID-19’s first battlefield: the nasopharynx

To get a detailed picture of what happens in the nasopharynx, the researchers sequenced the RNA in each cell, one cell at a time. (For a sense of all the work this entailed, each patient swab yielded an average of 562 cells.) The RNA data enabled the team to pinpoint which cells were present, which contained RNA originating from the virus – an indication of infection – and which genes the cells were turning on and off in response.

It soon became clear that the epithelial cells lining the nose and throat undergo major changes in the presence of SARS-CoV-2. The cells diversified in type overall. There was an increase in mucus-producing secretory and goblet cells. At the same time, there was a striking loss of mature ciliated cells, which sweep the airways, together with an increase in immature ciliated cells (which were perhaps trying to compensate).

The team found SARS-CoV-2 RNA in a a diverse range of cell types, including immature ciliated cells and specific subtypes of secretory cells, goblet cells, and squamous cells. The infected cells, as compared to the uninfected “bystander” cells, had more genes turned on that are involved in a productive response to infection.

A failed early immune response

The key finding came when the team compared nasopharyngeal swabs from people with different severity of COVID-19 illness:

  • In people with mild or moderate COVID-19, epithelial cells showed increased activation of genes involved with antiviral responses – especially genes stimulated by type I interferon, a very early alarm that rallies the broader immune system.
  • In people who developed severe COVID-19, requiring mechanical ventilation, antiviral responses were markedly blunted. In particular, their epithelial cells had a muted response to interferon, despite harboring high amounts of virus. At the same time, their swabs had increased numbers of macrophages and other immune cells that boost inflammatory responses.

“Everyone with severe COVID-19 had a blunted interferon response early on in their epithelial cells, and were never able to ramp up a defense,” says Ordovás-Montañés. “Having the right amount of interferon at the right time could be at the crux of dealing with SARS-CoV-2 and other viruses.”

Boosting interferon responses in the nose?

As a next step, the researchers plan to investigate what is causing the muted interferon response in the nasopharynx, which evidence suggests may also occur with the new SARS-CoV-2 variants. They will also explore the possibility of augmenting the interferon response in people with early COVID-19 infections, perhaps with a nasal spray or drops.

“It’s likely that, regardless of the reason, people with a muted interferon response will be susceptible to future infections beyond COVID-19,” Ordovás-Montañés says. “The question is, ‘How do you make these cells more responsive?'”

These maps represent gene expression in cells recovered from COVID-19 test swabs, based on single-cell RNA sequencing of more than 32,000 cells from 58 people. Each point in the maps represents an individual cell. At left, cell types from the nasopharynx are color-coded and arranged such that those with similar patterns of gene expression are in closer proximity. At right, red and blue colors indicate cell types that are enriched in COVID-19 (shown in red) and in healthy controls (blue). Credit: BioRxiv

+ – – – – – –

As critical illness in patients with COVID-19 is caused, in part, by inflammatory injuries that affect the lungs and lung blood vessels1, there are at least two distinct biological components to the mortality risk: susceptibility to viral infection and propensity to develop harmful pulmonary inflammation.

Susceptibility to life-threatening infections4 and immune-mediated diseases are both strongly heritable.

In particular, susceptibility to respiratory viruses5 such as influenza6 is heritable and known to be associated with specific genetic variants7.

In the case of COVID-19, one genetic locus – on chromosome 3p21.31 – has been repeatedly associated with hospitalization8,9. As with other virus-associated diseases10, there are several examples of loss-of-function variants affecting essential immune processes that lead to severe disease in young people, such as TLR711 and some genes implicated in type 1 interferon signalling, including the receptor subunit IFNAR212.

Genome-wide studies have the potential to reveal previously undescribed molecular mechanisms of critical illness in patients with COVID-19, which may provide therapeutic targets to modulate the host immune response to promote survival3.

Strong evidence indicates that critical illness caused by COVID-19 is qualitatively different from mild or moderate disease, even among hospitalized patients. There are multiple distinct disease phenotypes with differing patterns of symptoms13 and marked differential responses to immunosuppressive therapy2.

In patients without respiratory failure, there is a trend indicating that treatment with corticosteroids is harmful, whereas among patients with critical respiratory failure, there is a substantial benefit2.

On this basis, we consider patients with critical COVID-19 respiratory failure to have a distinct pathophysiology.

In the UK, the group of patients admitted to critical care is relatively homogeneous, with profound hypoxaemic respiratory failure being the archetypal presentation14. The active disease process in these patients is markedly responsive to corticosteroid therapy15 and is characterized by pulmonary inflammation including diffuse alveolar damage, influx of monocytes and macrophagess, mononuclear cell pulmonary artery vasculitis and microthrombus formation1,16.

Host-directed therapies have long been an aim for the treatment of the severe disease caused by respiratory viruses17. Identification of genetic loci associated with susceptibility to COVID-19 may lead to specific targets for the development or repurposing of drugs3.

The GenOMICC (Genetics Of Mortality In Critical Care, study has been recruiting patients with critical illness syndromes, including influenza, sepsis and emerging infections, for 5 years. To better understand the host mechanisms that lead to life-threatening disease in patients with COVID-19, we performed a genome-wide association study (GWAS) comparing critically ill patients with COVID-19 with controls from population genetic studies in the UK.

Reference link :

+ – – – – – –

More information: Carly G.K. Ziegler et al, Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19, Cell (2021). DOI: 10.1016/j.cell.2021.07.023


Please enter your comment!
Please enter your name here

Questo sito usa Akismet per ridurre lo spam. Scopri come i tuoi dati vengono elaborati.